Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (July 8th Preview)
-
FDA approval—IgA nephropathy
The U.S. FDA approved Vera Therapeutics’ atacicept fusion protein, branded Trutakna, for adults with primary IgA nephropathy (IgAN). The accelerated approval makes Trutakna the first dual BAFF/APRIL inhibitor in the indication, with the label based on reduction in proteinuria. The FDA’s decision gives Vera a commercial head start and sets up an impending competitive landscape with Otsuka’s kidney disease therapy, which entered the market last year. Vera’s Trutakna is dosed once weekly via auto-injector. A confirmatory study (Origin 3) is already underway, with readouts expected in the third quarter, which will determine whether Trutakna’s effect on proteinuria translates into slower kidney function decline over longer follow-up.
-
Big Pharma dealmaking—AstraZeneca-Sino respiratory push
Sino Biopharmaceutical expanded its ties with AstraZeneca and GSK through new respiratory-focused deals. AstraZeneca will license rights to Sino’s investigational lung disease candidate TQC3721, with $200 million upfront and additional milestone payments up to $1.9 billion. In a separate agreement, Sino gains China ownership of GSK’s marketed respiratory medicines Trelegy and Anoro, positioning Sino as importer, promoter and distributor in China. The transaction is designed to deepen Sino’s commercial reach for GSK’s respiratory portfolio. The announcements land amid heightened scrutiny of U.S.-and-EU pharma-to-China alliances, and they reinforce AstraZeneca’s growing investment in respiratory R&D and manufacturing in China.
-
Big Pharma M&A—Vertex to acquire Crinetics for endocrinology
Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals in a $10 billion cash deal, its largest ever, to broaden beyond cystic fibrosis and build an endocrinology franchise. Vertex will add Crinetics’ commercial therapy Palsonify for acromegaly and late-stage endocrine assets, including atumelnant for congenital adrenal hyperplasia. The deal follows Vertex’s push toward multiple commercial pillars and arrives with a price tag of $85 per share, supported by bridge financing commitments. Both boards have approved the transaction, with closing expected in the third quarter. For Crinetics, the acquisition also reframes the company’s near-term execution risk and monetization path, while for Vertex it consolidates specialty-market capabilities centered on rare endocrine biology.
-
Big Pharma acquisition—Novartis buys Myricx ADC payload platform
Novartis agreed to acquire Myricx Bio for up to $1.5 billion, aiming to strengthen its oncology pipeline with a next-generation antibody-drug conjugate (ADC) payload platform. Myricx’s approach centers on N-myristoyltransferase inhibitor (NMTi) payloads, designed to be delivered directly into tumor cells to address resistance and toxicity limitations seen with conventional ADC warheads. Novartis will pay $1.1 billion upfront and up to $400 million in milestones, with the acquisition expected to close in the second half of 2026. Myricx’s preclinical data reportedly supports activity across multiple solid tumors, including models resistant to topoisomerase and tubulin inhibitor payload classes. The deal signals Novartis’ continued platform-building strategy in oncology and expands its ADC payload innovation beyond current payload mechanisms.
-
Rare disease—Prime Medicine vs Beam gene-editing dispute
Prime Medicine won an arbitration ruling against Beam Therapeutics, determining that Prime’s work on its gene-editing therapy for alpha-1 antitrypsin deficiency (AATD) did not violate a 2019 agreement intended to prevent competitive overlap. The decision clears the way, at least for now, for Prime to proceed toward a clinical program planned to start this quarter. The ruling is a direct legal inflection point for two adjacent gene-editing companies spun out of the same lab, and it reduces near-term development risk tied to IP or agreement interpretation. Beam’s position is weakened by the arbitration outcome. The dispute’s resolution also highlights how deal and collaboration structures can constrain platform execution in gene editing, where multiple groups often target overlapping biology with different payload or editing designs.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.